USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products, which provide macro-nutrition. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. The company has a research collaboration agreement with Beijing University of Chinese Medicine for research in the field of traditional Chinese medicine. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.
IPO Year:
Exchange: NYSE
Website: usana.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/23/2023 | Buy | Sidoti | |
| 7/7/2022 | $78.00 → $53.00 | Hold → Underperform | Jefferies |
| 4/14/2022 | $86.00 | Neutral | DA Davidson |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)
4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)
4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)
4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)
4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)
4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)
4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)
4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)
4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)
4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Sidoti initiated coverage of USANA with a rating of Buy
Jefferies downgraded USANA from Hold to Underperform and set a new price target of $53.00 from $78.00 previously
DA Davidson initiated coverage of USANA with a rating of Neutral and set a new price target of $86.00
Roth Capital reiterated coverage of USANA Health Sciences with a rating of Buy and set a new price target of $126.00 from $107.00 previously
10-Q - USANA HEALTH SCIENCES INC (0000896264) (Filer)
8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)
8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)
SCHEDULE 13G - USANA HEALTH SCIENCES INC (0000896264) (Subject)
10-Q - USANA HEALTH SCIENCES INC (0000896264) (Filer)
SCHEDULE 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)
8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)
8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)
11-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)
S-8 - USANA HEALTH SCIENCES INC (0000896264) (Filer)
Fastest customizable press release news feed in the world
SALT LAKE CITY, Nov. 11, 2025 /PRNewswire/ -- USANA (NYSE:USNA), the global leader in cellular nutrition, is thrilled to announce that its fan-favorite MagneCal D supplement has officially earned the coveted ConsumerLab.com Seal of Approval—a gold-standard recognition for purity, potency, and scientific excellence.* With millions of Americans looking for ways to maintain their bone density, getting enough calcium, magnesium, and vitamin D isn't just a good idea—it's essential. That's where MagneCal D comes in, combining powerful nutrients to help maintain strong bones, keep yo
Community-wide effort addresses growing food insecurity among Utah children and families SALT LAKE CITY, Nov. 6, 2025 /PRNewswire/ -- In a powerful response to growing food insecurity affecting Utah families and the recent federal SNAP cutbacks, the USANA Foundation joined forces with community partners and volunteers on Wednesday, November 5, to assemble 3,000 bags of food for children and families facing food insecurity. The large-scale event, held at the USANA Foundation Headquarters in West Valley City, brought together hundreds of volunteers from organizations including t
SALT LAKE CITY, Nov. 3, 2025 /PRNewswire/ -- As business leaders worldwide focus on re-energizing workforces after years of upheaval, Kevin Guest, Executive Chairman of USANA Health Sciences (NYSE:USNA), is urging CEOs to lead with renewed authenticity, empathy, and moral clarity—principles he calls "the real foundation of sustainable success." "No doubt, technology and strategy will always matter," Guest said. "But what truly binds a company together is trust. When people feel seen, valued, and inspired, they do their best work, and that's how you create a culture that thrive
NEW YORK, Oct. 27, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600: Solstice Advance Materials Inc. (NASD: SOLS) will replace CarMax Inc. (NYSE:KMX) in the S&P 500, and CarMax will replace USANA Health Sciences Inc. (NYSE:USNA) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, October 31. S&P 500 and 100 constituent Honeywell International Inc. (NASD: HON) is spinning off Solstice Advance Materials in a transaction expected to be completed on October 30. Post spin-off, Honeywell International will remain in the S&P 500 and 100. CarMax and USANA Health Sciences no longer represent the large cap and small c
USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal third quarter ended September 27, 2025. Key Financial Results Third Quarter 2025 vs. Third Quarter 2024 Net sales of $214 million versus $200 million, representing 7% year-over-year growth. Net loss of -$6.5 million versus net earnings of $10.6 million. Diluted EPS of -$0.36 as compared with $0.56. Adjusted diluted EPS(1) of -$0.15 as compared with $0.56. Adjusted EBITDA(2) of $13.8 million versus $24.6 million. Direct selling Active Customers of 388,000 versus 452,000. Hiya Active Monthly Subscribers of 193,400. Q3 2025 Financial Performance Consolidated Results
USANA Health Sciences, Inc. (NYSE:USNA) ("the Company," "USANA") today announced that it has updated the timing of the release of its third quarter 2025 financial results, which had previously been scheduled for Tuesday, October 21, 2025. The Company will now report third quarter 2025 financial results after the close of market on Wednesday, October 22, 2025. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the follow
SALT LAKE CITY, Oct. 16, 2025 /PRNewswire/ -- USANA (NYSE:USNA), a global leader in cellular nutrition, is bringing a little more sunshine to wellness. Its top-rated Vitamin D supplement has officially earned the prestigious ConsumerLab.com Seal of Approval—a recognition reserved for products that deliver on purity, potency, and scientific precision. With approximately 42% of adults in the United States considered vitamin D deficient, having a vitamin D supplement on the market you can trust makes all the difference. "This isn't just a win for our product—it's a win for consum
USANA Health Sciences, Inc. (NYSE:USNA) today announced preliminary results for the third quarter ended September 27, 2025. The Company anticipates third quarter 2025 net sales will be approximately $214 million, which compares with $200 million in the prior-year period. Earnings from operations are expected to be $1.2 million for the current-year quarter, or 0.6% of net sales, as compared to $15.6 million in the third quarter of 2024. "Third quarter operating results came in below expectations, primarily due to softer-than-expected sales and Brand Partner productivity during the rollout of our enhanced Brand Partner compensation plan," said Jim Brown, President and Chief Executive Office
Dr. Kathryn Armstrong named a "Leadership Excellence Award" winner SALT LAKE CITY, Oct. 6, 2025 /PRNewswire/ -- USANA (NYSE:USNA) is proud to announce that its chief scientific officer, Dr. Kathryn Armstrong, has received the Women Tech Award from the Women Tech Council of Utah. The Women Tech Award is a distinguished recognition platform that celebrates women who are significantly contributing to the expansion and innovation within the technology sector. The program aims to enhance the visibility of women who are not only advancing technology but also inspiring the broader co
SALT LAKE CITY, Oct. 1, 2025 /PRNewswire/ -- As Emotional Wellness Month begins, Kevin Guest, executive chairman at USANA Health Sciences (NYSE:USNA), is spotlighting service as one of the most overlooked but powerful ways to strengthen mental well-being and emotional balance, especially for those in leadership roles. "Service is the clearest expression of our best selves," said Guest, bestselling author of All the Right Reasons: 12 Timeless Principles for Living a Life in Harmony. "When leaders serve others, it keeps them grounded, emotionally regulated, and focused on what t
Live finance-specific insights
USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal third quarter ended September 27, 2025. Key Financial Results Third Quarter 2025 vs. Third Quarter 2024 Net sales of $214 million versus $200 million, representing 7% year-over-year growth. Net loss of -$6.5 million versus net earnings of $10.6 million. Diluted EPS of -$0.36 as compared with $0.56. Adjusted diluted EPS(1) of -$0.15 as compared with $0.56. Adjusted EBITDA(2) of $13.8 million versus $24.6 million. Direct selling Active Customers of 388,000 versus 452,000. Hiya Active Monthly Subscribers of 193,400. Q3 2025 Financial Performance Consolidated Results
USANA Health Sciences, Inc. (NYSE:USNA) ("the Company," "USANA") today announced that it has updated the timing of the release of its third quarter 2025 financial results, which had previously been scheduled for Tuesday, October 21, 2025. The Company will now report third quarter 2025 financial results after the close of market on Wednesday, October 22, 2025. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the follow
USANA Health Sciences, Inc. (NYSE:USNA) today announced preliminary results for the third quarter ended September 27, 2025. The Company anticipates third quarter 2025 net sales will be approximately $214 million, which compares with $200 million in the prior-year period. Earnings from operations are expected to be $1.2 million for the current-year quarter, or 0.6% of net sales, as compared to $15.6 million in the third quarter of 2024. "Third quarter operating results came in below expectations, primarily due to softer-than-expected sales and Brand Partner productivity during the rollout of our enhanced Brand Partner compensation plan," said Jim Brown, President and Chief Executive Office
USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal second quarter ended June 28, 2025. Key Financial Results Second Quarter 2025 vs. Second Quarter 2024 Net sales of $236 million versus $213 million, representing 11% year-over-year growth. Net earnings of $9.7 million versus $10.4 million. Diluted EPS of $0.52 as compared with $0.54. Adjusted diluted EPS(1) of $0.74 as compared with $0.54. Adjusted EBITDA(2) of $30 million versus $27 million. Direct selling Active Customers of 418,000 versus 468,000. Hiya Active Monthly Subscribers of 200,400. Company reiterates fiscal year 2025 outlook. Q2 2025 Financial Performance C
USANA Health Sciences, Inc. (NYSE:USNA) today announced that second quarter 2025 results will be released after the close of market on Tuesday, July 22, 2025. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, July 23, 2025 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures
USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal first quarter ended March 29, 2025. Key Financial Results First Quarter 2025 vs. First Quarter 2024 Net sales of $250 million versus $228 million, representing year-over-year growth of 10% and 12% in constant currency. Net earnings of $9.4 million versus $16.5 million. Diluted EPS of $0.49 as compared with $0.86. Adjusted diluted EPS(1) of $0.73 as compared with $0.86. Adjusted EBITDA(2) of $30 million versus $33 million. Direct selling Active Customers of 459,000 versus 494,000. Hiya Active Monthly Subscribers of 224,000. Company reiterates fiscal year 2025 outlook. Q1 2025 Financia
USANA Health Sciences, Inc. (NYSE:USNA) today announced that first quarter 2025 results will be released after the close of market on Tuesday, April 22, 2025. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, April 23, 2025 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures hi
USANA Health Sciences, Inc. (NYSE:USNA) (the "Company") today announced financial results for its fiscal fourth quarter and fiscal year ended December 28, 2024. The Company completed the acquisition of a 78.8% controlling ownership stake of Hiya Health Products, LLC ("Hiya") on December 23, 2024. Consequently, the Company's fourth quarter and fiscal year 2024 include the effect of less than a week of Hiya's operating results, which were not significant to the Company's consolidated results for the same periods. In light of the Hiya acquisition, the Company is now including metrics for Adjusted diluted EPS(1) and Adjusted EBITDA(2). Net earnings, Diluted EPS, Adjusted diluted EPS(1) and Adju
USANA Health Sciences, Inc. (NYSE:USNA) today announced that fourth quarter and fiscal year 2024 results will be released after the close of market on Tuesday, February 25, 2025. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, February 26, 2025 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA de
Hiya is a fast-growing, emerging leader of high-quality children's health & wellness products. Broadens USANA's reach into the highly attractive direct-to-consumer channel driven by Hiya's powerful subscription model with runway for sustainable future growth. Expected to be immediately accretive to 2025 adjusted EBITDA. 9/30/2024 LTM net sales of $103 million, LTM net income of $19 million, and LTM adjusted EBITDA of $22 million. The Company will discuss the transaction during a conference call on Monday, December 23, 2024, at 5:00 PM ET. USANA Health Sciences, Inc. (NYSE:USNA) (the "Company," "USANA"), today announced its acquisition of a 78.8% controlling ownership stake in Hiya
Live Leadership Updates
NEW YORK, Oct. 27, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600: Solstice Advance Materials Inc. (NASD: SOLS) will replace CarMax Inc. (NYSE:KMX) in the S&P 500, and CarMax will replace USANA Health Sciences Inc. (NYSE:USNA) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, October 31. S&P 500 and 100 constituent Honeywell International Inc. (NASD: HON) is spinning off Solstice Advance Materials in a transaction expected to be completed on October 30. Post spin-off, Honeywell International will remain in the S&P 500 and 100. CarMax and USANA Health Sciences no longer represent the large cap and small c
SALT LAKE CITY, April 1, 2025 /PRNewswire/ -- USANA Health Sciences (NYSE:USNA) Executive Chairman Kevin Guest marks April's convergence of International Guitar Month and Stress Awareness Month, as a perfect pairing that celebrates the healing power of music for mental well-being. While music has long been heralded as a universal remedy, the guitar offers far more than just melodies. Studies, stories and specialists alike agree: playing the guitar is a proven method to reduce stress. A passionate, performing guitarist himself, Guest invites others to join the cause. "Music has
Dr. Kathryn Armstrong brings 17 years of scientific expertise to the company SALT LAKE CITY, Jan. 22, 2025 /PRNewswire/ -- USANA Health Sciences, Inc., a global leader in cellular nutrition, is proud to announce that Dr. Kathryn Armstrong, Ph.D., will be assuming the role of chief scientific officer at the company. Kathryn has served as USANA's executive vice president of research and development since July of 2024. Kathryn's predecessor, Dr. Rob Sinnott, announced his retirement at the end of 2024, but will continue to assist in the company's pursuit for scientific excellence as its senior scientific fellow.
SALT LAKE CITY, July 1, 2024 /PRNewswire/ -- Throughout July, Kevin Guest, executive chairman at USANA Health Sciences (NYSE:USNA), is emphasizing boosting social connections during "Social Wellness Month." Social wellness—the ability to form meaningful relationships and interact positively with others—not only enhances our emotional well-being but also significantly impacts our overall health. "Strong social connections reduce stress, improve mental health, and even extend life expectancy," said Guest. "In a world where digital interactions often replace face-to-face communic
SAN FRANCISCO, CA / ACCESSWIRE / December 12, 2023 / Helo Corp. (OTC:HLOC) ("Helo" or the "Company") is pleased to announce that Kevin Fuller has joined its executive team as president of Helo AI and chief marketing officer of Helo, effective December 1, 2023."We are delighted to welcome Kevin to our executive team," said Seán McVeigh, Helo's chief executive officer. "Kevin brings significant product development and marketing experience, arising from his previous roles as a senior executive with other leading technology and wellness companies. His passion and leadership add to the significant momentum of our Helo AI platform and upcoming products."Mr. Fuller, 53, served as cofounder and chie
USANA Health Sciences, Inc. (NYSE:USNA) today announced that consistent with the Company's planned succession strategy, Kevin Guest, USANA's Chief Executive Officer (CEO) since 2015 and Chairman of the Board since 2020, will transition to the role of Executive Chairman of the Company, effective July 1, 2023. At that time, Jim Brown, USANA's current President, will be named CEO of the Company. "It has been my great privilege to be part of USANA for over 30 years and to serve as CEO of this remarkable company for the last 8 years. I express my sincere appreciation for, and confidence in, USANA's extraordinary management team, employees and Associates for their relentless work in advancing US
USANA Health Sciences, Inc. (NYSE:USNA) today announced the appointment of Xia Ding to the company's board of directors effective October 11, 2021. Ms. Ding currently serves as Vice President of e-commerce Asia Pacific and Latin America at Nike and is well-regarded as an e-commerce and digital business leader. She has served in various management roles at several global online and omnichannel retailers, including Nike, JD.com and Hanesbrands. With the addition of Ms. Ding to the board as an independent director, the USANA board now has eight members, six of whom are independent. Kevin Guest, Chief Executive Officer and Chairman of the Board, commented, "I'm delighted to welcome Ms. Ding to
This live feed shows all institutional transactions in real time.
SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)
SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)
SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)
SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)
SC 13D/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)
SC 13D/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)
SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)
SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)